Health · Medical Research · 2 hrs ago
Pancreatic cancer vaccine triggers immune response but does not improve survival
A phase 2 trial tested camupepimut in 144 people with KRAS-mutated pancreatic cancer who had surgery and chemotherapy and no detectable cancer afterward.
Pancreatic cancer often returns after treatment, so researchers wanted to see whether the vaccine could help the body find and destroy cancer cells left behind.
The vaccine trains the immune system to recognize mutations in the KRAS gene, which are common in this cancer.
It did not significantly extend disease-free survival: the average was 23.8 months for vaccinated patients and 21.2 months for those who were observed without the vaccine.
Nearly 99 percent of vaccinated patients developed stronger T-cell responses against the mutations, and most still had detectable responses after 46 weeks.
Some patients may benefit more, including those with no detectable cancer DNA in their blood at the start of the study; patients who had not received radiotherapy also appeared to respond better.
Researchers plan to refine the vaccine and use the findings to develop a larger phase 3 trial.
A phase 2 trial of the experimental pancreatic cancer vaccine camupepimut found no statistically significant improvement in disease-free survival.
Nearly 99 percent of vaccinated patients developed increased T-cell responses against mutated KRAS.
The trial involved 144 patients with KRAS-mutated pancreatic cancer who had surgery and chemotherapy and no detectable cancer.
Researchers said the immune response could inform further development and a larger phase 3 trial.
- Who
- Mayo Clinic-led researchers studied 144 patients with KRAS-mutated pancreatic cancer.
- What
- The phase 2 trial found that camupepimut triggered immune responses but did not significantly improve disease-free survival.
- When
- Not stated
- Where
- Not stated
- Why
- Researchers tested whether the vaccine could help find and destroy cancer cells remaining after surgery and chemotherapy.
This story does not have two clearly opposing sides.
The trial enrolled patients who had no detectable signs of cancer.
Researchers randomly assigned 96 patients to receive the vaccine and observed the other 48 without it.
95.5 percent of vaccinated patients had detectable T-cell responses to KRAS mutations.
- Trial size
- 144 patients
- Vaccine group
- 96 patients
- Observation group
- 48 patients
- Disease-free survival
- 23.8 months in the vaccine group and 21.2 months in the observation group; the difference was not statistically significant
- T-cell response
- Nearly 99 percent of vaccinated patients developed increased responses against mutated KRAS
- Follow-up
- 95.5 percent had detectable T-cell responses over 46 weeks after the study began
1 source
What people are saying
The immune response is an important signal that helps us understand what is happening biologically and gives us important information for the next trial,
What is encouraging is that we were able to generate a strong immune response against KRAS mutations in nearly every patient we evaluated.